Immunocytochemical panel for distinguishing carcinoma cells from reactive mesothelial cells in pleural effusions

Cytopathology

Volumn 19, Issue 4, 2008, Pages 212-217

  Wu, G P ^a   Zhang, S S ^a   Fang, C Q ^a   Liu, S L ^a   Wang, E H ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cytodiagnosis; Cytopathology; Effusion; Immunocytochemistry; Lung cancer; Pleural

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER CYTODIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MESOTHELIUM CELL; PLEURA EFFUSION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; CHINA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, MESOTHELIAL; PLEURAL EFFUSION; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 46749123093     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2008.00559.x     Document Type: Article

References (23)

1. Ghayumi SM, Mehrabi S, Doroudchi M, Ghaderi A. Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients. Pathol Oncol Res 2005 11 : 236 41.
2. Afify AM, Stern R, Michael CW. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol 2005 32 : 145 50.
3. Souhami RL, Beverley PC, Bobrow LG, Ledermann JA. Antigens of lung cancer: results of the second international workshop on lung cancer antigens. J Natl Cancer Inst 1991 83 : 609 12.
4. Mason MR, Bedrossian CW, Fahey CA. Value of immunocytochemistry in the study of malignant effusions. Diagn Cytopathol 1987 3 : 215 21.
5. Sherman ME, Mark EJ. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma. Arch Pathol Lab Med 1990 114 : 845 51.
6. Afify AM, Al-Khafaji BM, Paulino AF, Davila RM. Diagnostic use of muscle markers in the cytologic evaluation of serous fluids. Appl Immunohistochem Mol Morphol 2002 10 : 178 82.
7. Queiroz C, Barral-Netto M, Bacchi CE. Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry. Acta Cytol 2001 45 : 18 22.
8. Ueda J, Iwata T, Ono M, Takahashi M. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion. Diagn Cytopathol 2006 34 : 6 10.
9. Afify A, Zhou H, Howell L, Paulino AF. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids. Acta Cytol 2005 49 : 621 6.
10. Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 2005 128 : 2298 303.
11. Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004 126 : 1757 63.
12. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005 32 : 151 5.
13. Ordonez NC. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003 27 : 1031 51.
14. Yaziji H, Battifora H, Barry TS et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006 19 : 514 23.
15. Shitrit D, Zingerman B, Shitrit AB et al. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 12-5 assays in pleural effusions: analysis of 116 cases and review of the literature. The Oncologist 2005 10 : 501 7.
16. Ko EC, Jhala NC, Shultz JJ, Chhieng DC. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. Am J Clin Pathol 2001 116 : 709 15.
17. Palaoro LA, Blanco AM, Gamboni M, Rocher AE, Rotenberg RG. Usefulness of ploidy, AgNOR and immunocytochemistry for differentiating benign and malignant cells in serous effusions. Cytopathology 2007 18 : 33 9.
18. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000 11 : 8 17.
19. Wu GP, Ba J, Zhao YJ, Wang EH. Diagnostic value of CEA, CYFRA 21-1, NSE and CA 125 assay in serum and pleural effusion of patients with lung cancer. Acta Cytol 2007 51 : 679 80.
20. Fetsch PA, Simsir A, Abati A. Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology. Diagn Cytopathol 2001 25 : 158 61.
21. Mocanu L, Cimpean AM, Raica M. Value of antimesothelioma HBME-1 in the diagnosis of inflammatory and malignant pleural effusions. Rom J Morphol Embryol 2006 47 : 351 5.
22. Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindan J. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer 2001 93 : 68 72.
23. Johnston WW. The malignant pleural effusion: a review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 1985 56 : 905 9.